UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-08, Vol.29 (22), p.2965-2971

2011

Volltextzugriff (PDF)

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Journal of clinical oncology, 2004-03, Vol.22 (5), p.777-784

2004

Volltextzugriff (PDF)

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Journal of clinical oncology, 2004-03, Vol.22 (5), p.785-794

2004

Volltextzugriff (PDF)

Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1324-1330

2000

Volltextzugriff (PDF)

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1652-1659

2016

Volltextzugriff (PDF)

Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3028-3028

2022

Volltextzugriff (PDF)

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

European journal of cancer (1990), 2019-02, Vol.108, p.120-128

2019

Volltextzugriff (PDF)

Overcoming kinase resistance in chronic myeloid leukemia

The international journal of biochemistry & cell biology, 2008, Vol.40 (3), p.334-343

2008

Volltextzugriff (PDF)

Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer

Journal of clinical oncology, 2000-06, Vol.18 (11), p.2293-2300

2000

Volltextzugriff (PDF)

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

European urology, 2017-02, Vol.71 (2), p.168-171

2017

Volltextzugriff (PDF)

Abstract 5167: Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5167-5167

2020

Volltextzugriff (PDF)

Abstract 1069: OBT076, a clinical-stage ADC, displays synergy with oxaliplatin and cisplatin in preclinical gastric cancer models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1069-1069

2022

Volltextzugriff (PDF)

A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9107-TPS9107

2016

Volltextzugriff (PDF)

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS616-TPS616

2016

Volltextzugriff (PDF)

Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel

European urology, 2016-06, Vol.69 (6), p.980-983

2016

Volltextzugriff (PDF)

Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5057-5057

2015

Volltextzugriff (PDF)

Abstract 1975: Potential novel Immuno-oncology mechanism revealed during translational phase I Immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1975-1975

2022

Volltextzugriff (PDF)

Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6029-6029

2016

Volltextzugriff (PDF)

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical breast cancer, 2018-10, Vol.18 (5), p.e919-e926

2018

Volltextzugriff (PDF)

Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2018-06, Vol.36 (18_suppl), p.LBA5005-LBA5005

2018

Volltextzugriff (PDF)

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-04, Vol.8 (4), p.423-428

2013

Volltextzugriff (PDF)

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2739-2744

1998

Volltextzugriff (PDF)

In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines

Oncology reports, 2008-02, Vol.19 (2), p.353-359

2008

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Overcoming kinase resistance in chronic myeloid leukemia

Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

Abstract 5167: Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile

Abstract 1069: OBT076, a clinical-stage ADC, displays synergy with oxaliplatin and cisplatin in preclinical gastric cancer models

A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC)

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI)

Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel

Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC)

Abstract 1975: Potential novel Immuno-oncology mechanism revealed during translational phase I Immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient

Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC)

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients

In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines

Suchergebnisse filtern